U.S. markets closed

PTC Therapeutics, Inc. (PTCT) in Focus: Stock Gains 5.2%

Zacks Equity Research

PTC Therapeutics, Inc. (PTCT) was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend of the company as the stock is now up 41.5% since Nov 19.

The stock witnessed one upward as well as one downward estimate revision in the past 30 days. The Zacks Consensus Estimate, however, moved up over the same time frame, suggesting that more solid trading could be ahead for PTC Therapeutics. So make sure to keep an eye on this stock going forward to see if the latest jump can turn into more strength down the road.

PTC Therapeutics carries a Zacks Rank #3 (Hold), while its Earnings ESP is negative.

However, some better-ranked stocks in the med-drugs industry include ArQule Inc. (ARQL), IGI, Laboratories, Inc. (IG) and Lannett Company, Inc. (LCI), all sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

PTC THERAPEUTICS INC (PTCT): Free Stock Analysis Report

ARQULE INC (ARQL): Free Stock Analysis Report

IGI LABORATORIES INC (IG): Free Stock Analysis Report

LAZARD GLOBAL TOTAL RETURN & INC (LGI): Free Stock Analysis Report

Zacks Investment Research